Authors
Latest:
Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMOCancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
Latest:
Discontinuing Teclistamab Early Yields Comparable Efficacy vs Continuous Therapy in RRMMThe 6- and 12-month PFS rates were 76.4% and 68.2%, respectively, in patients with relapsed/refractory multiple myeloma who discontinued treatment with teclistamab early.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROCA phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.
Latest:
CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETsThe NETRF lends funding to help discover new and emerging treatment options in neuroendocrine tumors, according to Anna Greene, PhD.
Latest:
Emerging Strategies to Manage Relapsed and/or Refractory Multiple MyelomaJames J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.
Latest:
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and TreatmentSurvivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Monitoring Response to Radioligand Therapy in Prostate CancerBiochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid TumorsA panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.
Latest:
Eryaspase Does Not Improve Efficacy vs Chemotherapy Alone in Advanced PDACThe incidence and severity of AEs with eryaspase/chemotherapy was generally consistent with previous reports of chemotherapy alone in advanced PDAC.
Latest:
Disorders of Sex Development and Malignant Germ Cell TumorsKey points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.
Latest:
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited InstitutionsSurgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
